Exploring the Impact of Perioperative Galacto-Oligosaccharides (GOS) on Stress, Anxiety and Cognition
Anxiety, Pain, Surgery
About this trial
This is an interventional prevention trial for Anxiety focused on measuring perioperative, surgery, pain, anxiety, post operative cognitive dysfunction, cognition
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing anterior cervical discectomy and fusion
Exclusion Criteria:
- Pregnancy
- Breast Feeding Women
- Diagnosis of Depression
- Diagnosis of mental or behavioral disorder
- Recent anxiolytic use (within 1 week of enrollment)
- Long-term opiate use (greater than 1 week prior to enrollment)
- Recent systemic steroid use (within 1 week of enrollment)
- Diagnosis of cancer
- Oral or intravenous antibiotic use within 1 month of enrollment
Sites / Locations
- Duke University Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Galacto-Oligosaccharides (GOS)
Maltodextrin (Placebo)
Clasado Biosciences Limited will provide Bimuno Pastilles for the clinical trial. Each pastille contains 0.92g GOS and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged GOS pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics. Each subject has an equal chance of receiving GOS or placebo. GOSn will be administered in the hospital when patient reinstitutes oral intake. GOS will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
Clasado Biosciences Limited will provide placebo (Maltodextrin) for the clinical trial. Each pastille contains maltodextrin and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics or placebo. Each subject has an equal chance of receiving GOS or placebo. Placebo will be administered in the hospital when patient reinstitutes oral intake. Placebo will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).